Experience

• 

  Parke-davis

  May 1997 - Sept 2000

  Medical representative

  Launch of Neurontin (Antiepileptic drug) and Cognex (1st pharmaceutical molecule indicated for Alzheimer's disease). Detail targeted Neurologists and Psychiatrists.

• 

  Pfizer

  Oct 2000 - Dec 2008

  Responsible for the entire Pfizer portfolio in Cyprus. Establish solid relationship with local distributor in order to exploit opportunities. Increase Neurontin sales and maintain the leading position in its market in 2001 and 2002. Create and implement marketing strategies and tactical plan to achieve annual objectives.

  • Cyprus Leader

    May 2003 - Dec 2008

  • Product Manager CNS

    Oct 2000 - Apr 2003
• 

  Merck healthcare

  Dec 2008 - now

  • 2021 Fertility & CM&E business performed 2.2% above OP in net sales • 2021 Endocrinology sales achievement 31% above OP net sales leveraging on competition withdrawal• Additional commercial responsibility of Fertility portfolio with bio-pharmaceutical products of Gonal-F, Pergoveris, Ovitrelle, Cetrotide & Crinone• New strategy implementation (focus at public sector) resulting sales performance of Gonal-f 20% above OP (gross sales)• Evaluation of several profitable growth projects such as:o Saizen new dosage of 12mg leading to lower CoGs. Non go project due to higher IRP risko Ovitrelle PFS launch resulting higher EBIT and elimination parallel export threato Slim pack of Gonal-f & Pergoveris • Plan of action implementation resulting the improvement of reimbursement status of Pergoveris in order to deliver growth through public sector (December 2021)• Cardiovascular gain #1 position in β-blockers market both in terms of values & sales• Introduction of new dosages of Euthyrox NF in Cyprus to strengthen of leadership in the Thyroids market Show less • Additional commercial responsibility of Growth Hormone portfolio with bio-pharmaceutical exclusively hospital line product of Saizen® • 2018 CM&E business performed 1% above OP and 11% growth vs LY in net sales at CM portfolio• 2019 sales performance was cumulatively on target (CM 3% above OP & Endo -1% vs OP)• 2020 CM&E business performed 11% above OP• New business model as EBIT improvement for Diabetes franchise in Greece through 3rd partnership with Greek pharmaceutical company• Launch of Euthyrox NF (best in class Levothyroxine in the market in terms of stability & precision) Show less • • 2017 CM business performed 8% above OP in net sales (including impact of local Rebates & Claw back)• Full business case (incl. P&L analysis) approval for the creation of entire commercial structure (marketing & sales force) & commercial responsibility of new BU Cardiovascular, Metabolism that includes Cardiovascular, Diabetes and Thyroid portfolio both for Greece & Cyprus • Business Development responsibility. More specifically to explore and leverage every potential commercial opportunity through new partnerships that can benefit Merck P&L and full responsibility of LCM projects• Emconcor launch to enhance Bisoprolol usage at Chronic Heart Failure patients Show less Creating Annual Business Development Plan in order to achieve company’s profitable growth and support core strategies such as:o Complete the consolidation of General Medicine portfolio in Merck A.E. Hellaso Explore other commercial opportunities within Merck Groupo Evaluate & collaborate with Regional BD for proposed projects that strategically fits into Greek organizationResponsible for the growth of entire portfolio in Cyprus and create new company image for Merck among all customers. Show less 1. Create a new BU of CMC & GM portfolio of Merck Serono in Greece (4 products). Negotiate new agreements with 3rd parties in order to start invoice this portfolio through Greek affiliate.2. Consolidation of Merck Serono entire portfolio (Neurodegenerative desease, Fertility, Endocrinology, CMC & GM, Oncology) under one distributor in Cyprus. Collaborate with new partner to increase sales and profitability.Create new sales team to provide necessary support to all products.3. Find new opportunities that strategically fit well in our sales & marketing structure in order to strengthen our position in Greek & Cypriot market. Show less

  • BU Head Fertlity & CM&E

    Jan 2021 - now

  • BU Head of Cardiovascular, Metabolism & Endocrinology

    Jun 2018 - Dec 2020

  • BU Head of Cardiovascular, Metabolism

    Jan 2017 - May 2018

  • 3P Business Manager

    Jan 2015 - Dec 2016

  • Business Development & Cyprus Manager

    Sept 2012 - Dec 2014

  • BU CardioMetabolic Care & General Medicine, Cyprus & Business Development Manager

    Dec 2008 - Sept 2012